Selumetinib in combination with dexamethasone for the treatment of relapsed/refractory RAS-pathway mutated paediatric and adult acute lymphoblastic leukaemia (SeluDex): study protocol for an international, parallel-group, dose-finding with expansion phase I/II trial.
Tobias MenneDaniel SladeJoshua S SavageSarah JohnsonJulie IrvingPamela KearnsRuth PlummerGeoff ShentonGareth J VealBritta VormoorJosef VormoorLucinda BillinghamPublished in: BMJ open (2022)
ISRCTN92323261.
Keyphrases
- liver failure
- acute lymphoblastic leukemia
- acute myeloid leukemia
- emergency department
- intensive care unit
- clinical trial
- wild type
- study protocol
- low dose
- diffuse large b cell lymphoma
- phase ii
- high dose
- multiple myeloma
- phase iii
- hodgkin lymphoma
- drug induced
- randomized controlled trial
- combination therapy
- aortic dissection
- open label
- hepatitis b virus
- smoking cessation
- double blind